BioSpace News Archive

Pacific Biosciences of California, Inc. announced that it intends to offer and sell $85.0 million of shares of its common stock and a selling stockholder intends to offer 1,304,348 of common stock shares in an underwritten public offering.

Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology based therapies for prevalent inflammatory conditions, announced today that the second group in the Phase I inhaled Ampion™ clinical study is being treated following clearance by the Safety Monitoring Committee

Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb par

As COVID-19 continues to set new records nationwide, the importance of understanding the difference in accuracy between temporal artery thermometers (TAT) and non-contact devices – now used widely for public temperature screenings – is of paramount importance

Bolt Biotherapeutics, a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems, today presented the trial design of its ongoing Phase 1/2 clinical trial and preclinical data demonstrating proof-of-concept of its lead clinical drug candidate, BDC-1001.

BioAssured, the rapidly growing company specializing in mitigating the spread of harmful microorganisms through multi-layered sanitization solutions, is thrilled to announce Claire Fournier as their new Vice President of Business Development.

Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today provided a corporate update and reported financial results for the third quarter ended September 30, 2020. “I am proud of the Vir team’s effort and success in accelerating our lead SARS-CoV-2 product candidate, VIR-7831, into a global Phase 3 trial, particularly in light of the more than 141,000 new C

BD, a leading global medical technology company, announced its rapid, point-of-care, SARS-CoV-2 antigen test for use on the BD Veritor™ Plus System has been authorized for use by Health Canada under Interim Order.

Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian , Ph.D., will deliver a corporate presentation as part of the Stifel Healthcare Conference 202

- Enrollment of PLN-74809 Phase 2a 12-week trials in IPF and PSC progressing - Phase 2a PET imaging trial of PLN-74809 in IPF enrolling - Completed dosing of an extended Phase 1 dose escalation trial of PLN-74809 in healthy volunteers